Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia

Laetitia M O de Kort, Esther T Kok, Trudy N Jonges, Peter F W M Rosier, J L H Ruud Bosch

Research output: Contribution to journalArticle (Academic Journal)peer-review

17 Citations (Scopus)

Abstract

OBJECTIVE: To investigate urodynamic, symptomatic, and histologic effects of intraprostatic injection with Ona botulinum toxin A for benign prostatic hyperplasia.

METHODS: Patients >55 years with symptomatic benign prostatic hyperplasia failing medical therapy were treated. Inclusion criteria were International Prostate Symptom Score >7, prostate volume 30-50 cm(3), and urodynamic bladder outlet obstruction >Schäfer grade 2. A transrectal intraprostatic injection of 200 IU Ona botulinum toxin A was given. Filling cystometry and pressure flow studies were performed at 3, 6, and 12 months post injection. International Prostate Symptom Score, International Prostate Symptom Score quality of life, prostate-specific antigen, and prostate volume were measured up until 12 months; prostate biopsies before and after Ona botulinum toxin A injection were done for histology and cell proliferation.

RESULTS: Fifteen men (mean age 64.9 years) were included. Ona botulinum toxin A injection was well tolerated with few complications. Postvoid residual improved (170 to 80 mL), but maximum flow rate and bladder outlet resistance parameters did not change during follow-up. International Prostate Symptom Score and International Prostate Symptom Score quality of life improved (22 to 13 and 5 to 2, respectively), whereas prostate-specific antigen and prostate volume remained unaltered. Cell proliferation did not decrease and in 37% and 64% of pre- and posttreatment biopsies, respectively, some degree of prostatitis was found. Ten of 15 patients eventually underwent transurethral prostate resection because of persisting symptoms.

CONCLUSION: Intraprostatic Ona botulinum toxin A for symptomatic benign prostatic hyperplasia did not affect urodynamic outcomes, except for postvoid residual. Although symptom scores improved, we were not able to show change in prostate volume, prostate-specific antigen, or histologic outcomes. A placebo effect of intraprostatic Ona botulinum toxin A could not be ruled out.

Original languageEnglish
Pages (from-to)889-93
Number of pages5
JournalUrology
Volume80
Issue number4
DOIs
Publication statusPublished - Oct 2012

Bibliographical note

Copyright © 2012 Elsevier Inc. All rights reserved.

Keywords

  • Aged
  • Botulinum Toxins, Type A
  • Humans
  • Injections, Intralesional
  • Male
  • Middle Aged
  • Neuromuscular Agents
  • Organ Size
  • Prostate
  • Prostate-Specific Antigen
  • Prostatic Hyperplasia
  • Prostatism
  • Statistics, Nonparametric
  • Urinary Bladder Neck Obstruction
  • Urodynamics

Fingerprint

Dive into the research topics of 'Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this